Link to Full Article Melbourne, Australia – 5 August 2020: Adherium Limited (ASX: ADR) a leader in digital inhaled device adherence, remote monitoring and data management solutions, has appointed Mr Geoff Feakes as Chief Technology Officer (CTO) leading the Company’s R&D and Innovation teams supporting Adherium’s revised business strategy. Mike Motion, Adherium CEO noted: “I […]
Protocol amendment agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value Study two thirds enrolled. Recruitment now expected to complete by year end Planned study interim safety review to be announced in August 2020 Brighton, United Kingdom – 27 July 2020 – Destiny Pharma plc (AIM: DEST), […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-07-27 05:24:592020-07-31 05:29:49Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections
Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline La Jolla, Calif., USA; Szeged and Budapest, Hungary July 15, 2020 – CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-07-21 04:00:042020-07-24 04:01:55CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies
Link to Full Article Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone The percentage of patients requiring invasive mechanical ventilation was 2.8 times lower with Auxora plus standard of care compared to standard of care alone Treating 2.6 […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-07-16 03:26:412020-07-17 03:28:06CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia
Link to Full Article Twenty-three leading biopharmaceutical companies have joined forces to invest $1 billion in a fund to develop new antibiotics, which are needed urgently to fight the worldwide rise in antimicrobial-resistant superbugs. The AMR Action Fund, aims to bring 2-4 new antibiotics to patients by 2030. Through the AMR Action Fund, pharmaceutical companies will join […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-07-10 03:29:262020-07-17 03:30:29Pharma companies join forces to launch $1 billion fund to develop new antibiotics by 2030
Link to Full Article Adherium Limited ACN 605 352 510 (Company) (ASX: ADR) has undertaken an allotment of fully paid ordinary shares (Shares) under its Employee Share Plan. Details of the allotment are contained in the Appendix 2A filed by the Company on 30 June 2020. The Company gives notice pursuant to section 708A(5)(e) of […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-06-30 03:22:212020-07-17 03:24:33Cleansing notice under section 708A of the Corporations Act 2001 (Cth)
Link to Full Article On 23 June 2020, the UK patent office issued the Microscaffold patent (GB2544748A). Our custom Microscaffolds can be made from a large variety of materials and sizes, tailored towards their desired application. Their open, porous, three-dimensional structure allows for facile cell attachment and integration over a large range of cell types. These scaffolds […]
Link to Full Article Non-dilutive funding to be used to advance the company’s second phage-based therapeutic candidate in a Phase 1b/2 clinical study MARINA DEL REY, Calif., June 17, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-06-17 04:18:342020-06-19 04:20:15Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections
Link to Full Article AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp® Cambridge, UK., 15 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, presented positive results for the Phase I clinical trial of its ultra-rapid acting […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-06-15 04:13:182020-06-19 04:17:13ARECOR PRESENTS POSITIVE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA-RAPID ACTING INSULIN
Cambridge, UK., 10 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-06-10 04:02:452020-06-12 04:08:13ARECOR ANNOUNCES ORAL PRESENTATION OF THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING INSULIN, AT THE AMERICAN DIABETES ASSOCIATION 80TH SCIENTIFIC SESSIONS
Adherium appoints Mr Geoff Feakes as Chief Technology Officer
/in AdheriumLink to Full Article Melbourne, Australia – 5 August 2020: Adherium Limited (ASX: ADR) a leader in digital inhaled device adherence, remote monitoring and data management solutions, has appointed Mr Geoff Feakes as Chief Technology Officer (CTO) leading the Company’s R&D and Innovation teams supporting Adherium’s revised business strategy. Mike Motion, Adherium CEO noted: “I […]
Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections
/in Destiny PharmaProtocol amendment agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value Study two thirds enrolled. Recruitment now expected to complete by year end Planned study interim safety review to be announced in August 2020 Brighton, United Kingdom – 27 July 2020 – Destiny Pharma plc (AIM: DEST), […]
CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies
/in CalcimedicaUnder the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline La Jolla, Calif., USA; Szeged and Budapest, Hungary July 15, 2020 – CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of […]
CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia
/in CalcimedicaLink to Full Article Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone The percentage of patients requiring invasive mechanical ventilation was 2.8 times lower with Auxora plus standard of care compared to standard of care alone Treating 2.6 […]
Pharma companies join forces to launch $1 billion fund to develop new antibiotics by 2030
/in Destiny PharmaLink to Full Article Twenty-three leading biopharmaceutical companies have joined forces to invest $1 billion in a fund to develop new antibiotics, which are needed urgently to fight the worldwide rise in antimicrobial-resistant superbugs. The AMR Action Fund, aims to bring 2-4 new antibiotics to patients by 2030. Through the AMR Action Fund, pharmaceutical companies will join […]
Cleansing notice under section 708A of the Corporations Act 2001 (Cth)
/in AdheriumLink to Full Article Adherium Limited ACN 605 352 510 (Company) (ASX: ADR) has undertaken an allotment of fully paid ordinary shares (Shares) under its Employee Share Plan. Details of the allotment are contained in the Appendix 2A filed by the Company on 30 June 2020. The Company gives notice pursuant to section 708A(5)(e) of […]
UK patent office issued the Microscaffold patent (GB2544748A)
/in ElectrospinningLink to Full Article On 23 June 2020, the UK patent office issued the Microscaffold patent (GB2544748A). Our custom Microscaffolds can be made from a large variety of materials and sizes, tailored towards their desired application. Their open, porous, three-dimensional structure allows for facile cell attachment and integration over a large range of cell types. These scaffolds […]
Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections
/in Armata PharmaceuticalsLink to Full Article Non-dilutive funding to be used to advance the company’s second phage-based therapeutic candidate in a Phase 1b/2 clinical study MARINA DEL REY, Calif., June 17, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today […]
ARECOR PRESENTS POSITIVE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA-RAPID ACTING INSULIN
/in ArecorLink to Full Article AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp® Cambridge, UK., 15 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, presented positive results for the Phase I clinical trial of its ultra-rapid acting […]
ARECOR ANNOUNCES ORAL PRESENTATION OF THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING INSULIN, AT THE AMERICAN DIABETES ASSOCIATION 80TH SCIENTIFIC SESSIONS
/in Arecor, UncategorisedCambridge, UK., 10 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes […]